Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.43 |
| ▸ | HRH1 | P35367 | 3/20 | 0.42 |
| ▸ | IKBKB | O14920 | 4/20 | 0.38 |
| ▸ | CHUK | O15111 | 3/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.36 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.36 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1062389 | 0.71 | CHRNA7 (0.37) | — | |
| SCHEMBL16234789 | 0.71 | ALDH1A1 (0.46) | PDE4ASLC6A3 | |
| SCHEMBL20064602 | 0.70 | PDE4A (0.51) | HTR6PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15650817 | 0.68 | PDE4B (0.48) | PDE4APDE4BROCK1HRH1PRKCZ | |
| SCHEMBL13963719 | 0.67 | ACVR1B (0.47) | PDE4BROCK1HRH1HTR1ASLC6A2 | |
| SCHEMBL3621040 | 0.67 | NCF1 (0.40) | — | |
| SCHEMBL2252843 | 0.66 | HTR1A (0.51) | ROCK1HRH1PRKCZHTR1ASLC6A2 | |
| SCHEMBL13973475 | 0.66 | HRH1 (0.46) | PDE4BROCK1HRH1IKBKBCHUK | |
| SCHEMBL31122248 | 0.66 | ROCK1 (0.62) | ROCK1HRH1IKBKBPRKCZSLC6A2 | |
| Hydrochloric Acid SCHEMBL6047107 | 0.66 | NCF1 (0.40) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582767-B2 | Substituted sulphonamide compound and uses thereof | BIOVITRUM AB (PUBL.) (SE) | 2009-09-01 | — | — | US | disclosed |
| EP-1896460-B1 | BENZOFURANYL DERIVATIVES AS 5-HT6-RECEPTOR INHIBITORS | BIOVITRUM AB PUBL (SE) | 2009-07-22 | — | — | EP | disclosed |
| EP-1896460-A1 | BENZOFURANYL DERIVATIVES AS 5-HT6-RECEPTOR INHIBITORS | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | disclosed |
| US-20060293361-A1 | N-[7-(4-piperidinyl)oxy-1-benzofuran-5-yl]-5-hydroxymethyl-2-methoxybenzenesulfonamide; the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, CNS disorders, to achieve reduction of body weight and/or body weight gain | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2006-12-28 | — | — | US | disclosed |
| WO-2006134150-A1 | BENZOFURANYL DERIVATIVES AS 5-HT6-RECEPTOR INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293361-A1 | N-[7-(4-piperidinyl)oxy-1-benzofuran-5-yl]-5-hydroxymethyl-2-methoxybenzenesulfonamide; the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, CNS disorders, to achieve reduction of body weight and/or body weight gain | GPR119, CNR2, SULT1E1 | HTR6 598/4885PDE4A 2128/4885PDE4B 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.